Korro Bio Inc
KRRO
NASDAQ
Biotechnology
$13.28
USD
-0.01 (-0.08%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $195.70M
Volume 47.1K
Revenue
$2.38M
TTM
-62.1%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-106.64M
TTM
-16.7%
YoY
Operating Cash Flow
$-67.95M
TTM
-1.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.5 | 1.1 | 1.3 | 0.0 | 0.0 |
YoY Growth | — | — | -43.1% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.5 | 1.1 | 1.3 | 0.0 | 0.0 |
Selling, General & Administrative | 7.3 | 6.5 | 6.2 | 7.5 | 6.5 |
Other Operating Expenses | 1.2 | 0.0 | 34.5 | 0.0 | 0.0 |
Total Operating Expenses | 28.7 | 20.3 | 51.7 | 20.4 | 20.1 |
Operating Income | -27.2 | -19.2 | -50.4 | -20.4 | -20.1 |
EBITDA | -24.7 | -18.1 | -15.2 | -20.1 | -19.7 |
Other Income / Expense | 1.4 | 1.2 | 1.0 | 0.9 | 1.3 |
Total Other Income / Expense | 1.4 | 1.2 | 1.0 | 0.9 | 1.3 |
Income Before Income Taxes | -25.8 | -18.1 | -49.4 | -19.5 | -18.8 |
Income Taxes | 0.0 | 0.0 | 0.6 | 0.1 | 0.1 |
Net Income | -25.8 | -18.1 | -50.0 | -19.6 | -18.9 |
Consolidated Net Income / Loss | -25.8 | -18.1 | -50.0 | -19.6 | -18.9 |
Net Income Attributable to Common Shareholders | -25.8 | -18.1 | -50.0 | -19.6 | -18.9 |
Basic EPS | -$2.74 | -$1.92 | -$5.31 | -$1.69 | -$1.07 |
Diluted EPS | -$2.74 | -$1.92 | -$5.31 | -$1.69 | -$1.07 |
Basic Shares Outstanding | 9.4M | 9.4M | 9.4M | 11.6M | 17.6M |
Diluted Shares Outstanding | 9.4M | 9.4M | 9.4M | 11.6M | 17.6M |